Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer: A Single-Center, Open-Label, Single-Arm, Phase 2 Trial
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 51
- 试验地点
- 1
- 主要终点
- Pathological complete response
研究概览
简要总结
Immunoscore has been reported to be superior to microsatellite instability staging in predicting the disease-specific recurrence and survival for patients with colorectal cancer. However, the relationship between Immunoscore and its impact on patient's response to PD-1 blockade remains to be elucidated. This phase II, prospective, open label study is designed to evaluate the efficacy and safety of combination neoadjuvant chemoradiotherapy (nCRT) with the anti-PD-1 antibody sintilimab for intermediate/high Immunoscore locally advanced rectal cancer.
详细描述
This study investigates the safety, tolerability, and feasibility of sintilimab, an immunotherapy agent, in combination with nCRT for treatment of patients with intermediate/high Immunoscore locally advanced rectal cancer. Sintilimab is an anti-PD-1 inhibitor that works by enhancing the functional activity of the target immune cells to facilitate tumor regression and ultimately immune rejection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years and ≤75 years.
- •Willing and able to provide written informed consent for participation in this study.
- •Treatment-naive patients with histological or cytological documentation of rectal adenocarcinoma (<12 cm from the anal verge).
- •Clinical stage of T3/T4 or N positive and M0, before nCRT.
- •Non complicated primary tumor (complete obstruction, perforation, bleeding).
- •Subjects with an intermediate or high immunoscore (according to Immunoscore®).
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Women of childbearing potential who consent to practicing contraception during the period from giving informed consent to at least 23 weeks after the last dose of therapy.
- •Women of childbearing potential with a negative serum or urine pregnancy test within 24 hours prior to the start of study drug.
- •Subjects with normal organ and marrow function as defined below:
- •Leukocytes ≥ 3,000/k/uL; Absolute neutrophil count ≥ 1,500/k/uL; Platelet count ≥ 100,000/k/uL; Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); AST (SGOT) ≤ 2.5 x institutional upper limit of normal (ULN); ALT (SGPT) ≤ 2.5 x institutional upper limit of normal (ULN); Serum creatinine ≤ 1.5 x institute upper limit of normal (ULN).
排除标准
- •Subjects with a history of a prior malignancy within the past 5 years, except for adequately treated basal cell or squamous cell skin cancer.
- •Subjects with a history of any arterial thrombotic event within the past 6 months. This includes angina (stable or unstable), myocardial infarction (MI), Transient Ischemic Attacks (TIA), or cerebralvascular accident (CVA).
- •Subjects with active lung disease (such as interstitial pneumonia, pneumonia, obstructive pulmonary disease, asthma) or active tuberculosis.
- •Subjects with any uncontrollable clinical problems, including but not limited to: active autoimmune disease, uncontrolled diabetes, uncontrolled hypertension, heart failure grade III/IV (NYHA-classification), or persistent or severe infection.
- •Subjects with a history of anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy.
- •Subjects with known allergy to the study drugs or to any of its excipients.
- •Current or recent (within 4 weeks prior to starting study treatment) treatment of another investigational drug or participation in another investigational study.
- •Breast- feeding or pregnant women.
- •Subjects with significant unstable mental diseases or other medical diseases that may interfere with the safety of the subjects, obtaining informed consent, or compliance with the procedures for the clinical study.
研究组 & 干预措施
Chemoradiotherapy and PD1 inhibitor
Chemoradiotherapy and PD1 inhibitor
干预措施: Sintilimab (Drug)
结局指标
主要结局
Pathological complete response
时间窗: 1 month after surgery
Pathological complete response will be evaluated with American Joint Committee on Cancer (AJCC) Cancer Staging
次要结局
- Tumor regression grade(during the 3-year period of follow-up)
- Number of participants with surgical complications(30 days after surgery)
- Local recurrence(3 years after the surgery)
- Tumor downstaging(during the 3-year period of follow-up)
- Margin-free (R0) resection rate(Immediately after the surgery)
- 3-year overall survival rate(3 years after the surgery)
- Correlation between minimal residual disease (MRD) and survival(3 years after the surgery)
- 3-year event-free survival rate(3 years after the surgery)
研究者
Yanhong Deng
Professor
Sun Yat-sen University